NGNE

SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)

10-Q - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026 Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment Topline data from Embolden™ registrational trial anticipated in 2H 2027 NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026 Initiated PPQ campaign to support BLA submission for NGN-401; completion of PPQ runs expected by end of 2026 Extended cash

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the "Inducement Grants") on August 3, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Li

– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors – Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026072830083

4 - Neurogene Inc. (0001404644) (Issuer)

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the "Inducement Grants") on July 6, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi

4 - Neurogene Inc. (0001404644) (Issuer)

8-K - Neurogene Inc. (0001404644) (Filer)

424B5 - Neurogene Inc. (0001404644) (Filer)

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offering price of $29.999999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.000001 per share and are exercisable immediately. The aggregate gross proceeds to Neurogene from the offering are expected to be

424B5 - Neurogene Inc. (0001404644) (Filer)

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Neurogene expects to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or wh

8-K - Neurogene Inc. (0001404644) (Filer)

47 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant, and all gaining ≥1 developmental milestone in the past 12 months Developmental milestones were gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of June 16, 2026 Dosing complete in the EmboldenTM registrational trial with no treatment-related SAEs or DLTs as of

4/A - Neurogene Inc. (0001404644) (Issuer)

4/A - Neurogene Inc. (0001404644) (Issuer)

4/A - Neurogene Inc. (0001404644) (Issuer)

3/A - Neurogene Inc. (0001404644) (Issuer)

8-K - Neurogene Inc. (0001404644) (Filer)

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 Topline data from Embolden anticipated in 2H 2027 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to be a potential best-in-class, one-time treatment fo

8-K - Neurogene Inc. (0001404644) (Filer)

Rodman & Renshaw initiated coverage of Neurogene with a rating of Buy and set a new price target of $70.00

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company's common stock to two new employees (the "Inducement Grants") on June 1, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi